Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jan 11;3:1346322. doi: 10.3389/fopht.2023.1346322

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 Ibrahim, Teo, Tan, Chan, Chandrasekaran, Lee, Tan, Mathur, Chan, Sim, Tan, Yeo and Cheung

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

A 83-year-old male with type 1 MNV was switched to faricimab after persistent SRF and a large PED despite having five-weekly injections of ranibizumab. (A) SD-OCT at the pre-switch visit (VA: 0.3 logMAR; CST: 276 µm; and MV: 8.11 mm³). (B) SD-OCT after the first faricimab injection demonstrating increased subretinal fluid (VA: 0.54 logMAR; CST 338 µm; and MV: 8.6 mm³). MNV, macular neovascularisation; SRF, subretinal fluid; PED, pigment epithelial detachment; SD-OCT, spectral domain optical coherence tomography; VA, visual acuity; CST, central subfield thickness; MV, macular volume.